Comparative Pharmacology
Head-to-head clinical analysis: AZILSARTAN MEDOXOMIL versus EDARBYCLOR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AZILSARTAN MEDOXOMIL versus EDARBYCLOR.
AZILSARTAN MEDOXOMIL vs EDARBYCLOR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Angiotensin II receptor blocker (ARB) that selectively inhibits angiotensin II binding to AT1 receptors, reducing vasoconstriction, aldosterone secretion, and sympathetic activity.
EDARBYCLOR is a fixed-dose combination of azilsartan medoxomil, an angiotensin II receptor blocker (ARB), and chlorthalidone, a thiazide-like diuretic. Azilsartan selectively blocks AT1 receptors, reducing angiotensin II-mediated vasoconstriction, aldosterone secretion, and renal sodium reabsorption. Chlorthalidone inhibits sodium-chloride cotransport in the distal convoluted tubule, increasing excretion of sodium, chloride, and water, thereby reducing plasma volume.
40 mg orally once daily. May increase to 80 mg once daily if needed.
One tablet (azilsartan medoxomil 40 mg / chlorthalidone 12.5 mg or 40 mg / 25 mg) orally once daily.
None Documented
None Documented
Clinical Note
moderateAzilsartan medoxomil + Benzydamine
"The risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Benzydamine."
Clinical Note
moderateAzilsartan medoxomil + Droxicam
"The risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Droxicam."
Clinical Note
moderateAzilsartan medoxomil + Loxoprofen
"The risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Loxoprofen."
Clinical Note
moderateTerminal half-life approximately 11 hours; supports once-daily dosing with sustained antihypertensive effect over 24 hours.
Terminal elimination half-life is approximately 11-12 hours for azilsartan medoxomil; clinical consequence: supports once-daily dosing for 24-hour blood pressure control
Biliary/fecal (55% unchanged), renal (42% as inactive metabolites, <1% unchanged)
Renal (approximately 60% as unchanged drug and metabolites), biliary/fecal (approximately 40%)
Category C
Category C
Angiotensin II Receptor Blocker
Angiotensin II Receptor Blocker/Thiazide Diuretic Combination
Azilsartan medoxomil + Clonixin
"The risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Clonixin."